Sitemap

Pages

• 23rd GFPP Meeting on peptides and proteins
• About us
  • Fmoc you
  • Follow us
  • History
  • Made in France
  • How to order
  • News & events
    • Cancer Immunotherapy & Immunomonitoring (CITIM) International Conference 2023
    • European Peptide Society (EPS) 26th Polish Peptide Symposium (PPS)
    • SB-PEPTIDE’s new premises
    • Sociedade Portuguesa de Imunologia (SPI) XLVIII Annual Meeting 2024
    • EACR conference « DEFENSE IS THE BEST ATTACK » on Immuno-Oncology Breakthroughs
    • Sociedade Portuguesa de Imunologia (SPI) XLVIII Annual Meeting 2023
  • Recent citations
  • Careers
  • Contact
  • Quote request
• Cookie Policy (EU)
• EACR conference « Cellular Bases for Patient Response to Cancer Therapies »
• European Peptide Symposium
• Glucagon (1-29) – Human, Porcine (CAS: 16941-32-5)
• Home
• MOG Peptides Pool sequences
• Privacy Policy
• Process development
  • Analytical method
  • Impurity profiling
  • Peptide Process
  • Peptide purification method development
  • Peptide stability studies
  • Peptide synthesis method development
  • Pharmacokinetics
    • ADME studies
  • Solubility studies
  • Peptide stability analysis
• Produit
• Quality
• Sitemap
• Special congress discount
• Technical Support
  • Amino acids chart and reference table
  • Peptide decontamination guidelines
  • Peptide ordering guide
  • Peripheral Blood Mononuclear Cells (PBMC) isolation protocol
  • Proteasomal cleavage prediction database
  • Peptide solubility guidelines
  • Peptide design
  • Handling & storage
• Test produit
• Peptide services
  • Custom PNA synthesis service
    • Peptide nucleic acids
  • Custom peptide synthesis
    • Síntesis de Péptidos
    • Synthèse de peptides
  • Peptide modifications
    • Bioconjugation service for peptides, antibodies, oligos…
    • KLH peptide conjugation service
    • Fluorescent labeling
    • Affinity tag peptides
    • Folding & cyclization
    • Immunogenic & branched peptides
    • Special amino acids
      • Cysteine Carbamidomethylation (Cysteine CAM)
      • Diazirine peptides: incorporation of Photo-Leucine and Photo-Methionine
      • Phosphorylated peptide synthesis
    • N-ter/internal/C-ter modifications
      • DOTA/NOTA functionalization
      • Peptide-Drug Conjugate
        • Doxorubicin – Cytotoxic payload
        • MMAE – Cytotoxic payload
    • Special request
  • Peptide library synthesis service
    • Biological assays
    • Epitope mapping
    • Peptide library for proteomics
    • Vaccine development
  • Peptide catalog
    • Anti-inflammatory peptides
    • Antimicrobial peptides – AMP
      • Abaecin
      • Apidaecin IB
      • Cecropin A
      • Cycloviolacin O2 peptide
      • hBD-2 peptide – human Beta Defensin 2
      • Hepcidin-25 (LEAP-1 peptide)
      • LL-37 peptide (CAP-18)
      • Magainin-1
      • Mastoparan peptide
      • mBD3 peptide – mouse Beta Defensin 3
      • Scrambled LL-37 peptide
      • T22 peptide
    • Bombesin peptides
      • Bombesin – Potent natural agonist of the mammalian receptor GRPR
    • Cell-penetrating peptides – CPP
      • TAT (47-57) peptide
      • (Arg)9 peptide
      • Penetratin peptide
    • COVID-19 peptides
      • ACE2 – Angiotensin-Converting enzyme 2 – peptide library
      • Biotin-SARS-CoV-2 Spike RBD 319-335 peptide
      • Biotin-SARS-CoV-2 Spike RBD 336-347 peptide
      • Biotin-SARS-CoV-2 Spike RBD 348-357 peptide
      • Biotin-SARS-CoV-2 Spike RBD 352-365 peptide
      • Biotin-SARS-CoV-2 Spike RBD 371-394 peptide
      • Biotin-SARS-CoV-2 Spike RBD 395-430 peptide
      • Biotin-SARS-CoV-2 Spike RBD 513-520 peptide
      • Biotin-SARS-CoV-2 Spike RBD 523-541 peptide
      • Biotin-SARS-CoV-2 Spike RBM 438-458 peptide
      • Biotin-SARS-CoV-2 Spike RBM 450-473 peptide
      • Biotin-SARS-CoV-2 Spike RBM 480-496 peptide
      • Biotin-SARS-CoV-2 Spike RBM 500-509 peptide
      • SARS CoV-2 Spike (S) protein – Peptide library
      • SARS-CoV-2 Nucleocapsid (N) protein – Peptide library
      • SARS-CoV-2 Spike RBD 319-335 peptide
      • SARS-CoV-2 Spike RBD 336-347 peptide
      • SARS-CoV-2 Spike RBD 348-357 peptide
      • SARS-CoV-2 Spike RBD 352-365 peptide
      • SARS-CoV-2 Spike RBD 371-394 peptide
      • SARS-CoV-2 Spike RBD 395-430 peptide
      • SARS-CoV-2 Spike RBD 513-520 peptide
      • SARS-CoV-2 Spike RBD 523-541 peptide
      • SARS-CoV-2 Spike RBM 438-458 peptide
      • SARS-CoV-2 Spike RBM 450-473 peptide
      • SARS-CoV-2 Spike RBM 480-496 peptide
      • SARS-CoV-2 Spike RBM 500-509 peptide
      • Spike Protein (SARS-CoV-2) Peptide Pool
      • Variants package of SARS CoV-2 Spike (S) protein mutation – Peptide library
    • Enzyme related peptides
    • Gel forming peptides
      • Max-1 peptide
    • GLP-1 peptides
    • GPCR modulators
      • Apelin-36 (human) – CAS: 252642-12-9
      • [Pyr1]apelin-13 (human) (CAS: 217082-60-5)
    • Hematology related peptides
    • Hormones
      • Alpha mating factor – WHWLQLKPGQPMY
      • Calcitonin, human – Agonist of the calcitonin receptor CTR
      • CCL2 (MCP-1)
      • Exendin 4 – Potent GLP-1R agonist
      • Protirelin – Thyrotropin-releasing hormone (TRH) (CAS: 24305-27-9)
      • RANTES (CCL5)
      • [Glu2]-TRH peptide (CAS: 85541-78-2)
    • Ion channel blockers
    • Multiple sclerosis peptides
      • Experimental Autoimmune Encephalomyelitis KIT
      • Human MOG Peptides Pool
      • MBP (1-11) human: Ac-ASQKRPSQRHG CAS 106128-98-7
      • MBP (84-97) – VVHFFKNIVTPRTP
      • MBP (85–99) – EKPKVEAYKAAAAPA
      • MOG (183-191) – FVIVPVLGP
      • MOG (35-55), human peptide
      • MOG (91-108) peptide – SDEGGYTCFFRDHSYQEE
      • MOG (92-106) peptide – DEGGYTCFFRDHSYQ
      • MOG (97-108) peptide- TCFFRDHSYQEE
      • PLP (139-151) peptide – HSLGKWLGHPDKF – [CAS 122018-58-0]
      • PLP (178-191): NTWTTCQSIAFPSK mouse, rat
      • Biotin-Mouse MOG (35-55) peptide
      • Mouse MOG (35-55) peptide
    • Neuroscience peptides
      • Amyloid beta peptides
      • Apolipoprotein E fragment (133-149) – COG133 : LRVRLASHLRKLRKRLL (CAS : 514200-66-9)
      • FMRFamide peptide
      • KLPGF peptide
      • MiniAp-4 peptide
      • Neuropeptide NPSF
      • Neuropeptide RFRP-1 (81-92)
      • Neuropeptide RFRP-2 (101-112)
      • Neuropeptide RFRP-3 (124-131)
      • Ovalbumin (154-159)
      • Ovotransferrin (328-332)
    • Other categories
      • 3x DYKDDDDK peptide
      • Angiotensin II
      • APYTFGQGTK peptide
      • Cysteine Peptide for DPRA tests
      • DYKDDDDK peptide
      • Lysine peptide for DPRA tests
      • SBCleaner – Peptide decontamination
      • TRAP-6 peptide
    • RGD peptides
    • Stable Isotope Labeled (SIL) peptides catalog
      • ADALQAGASQFETSAAK* – SIL Infliximab signature peptide
      • APYTFGQGTK* – SIL Adalimumab internal standard
      • ASGYTFTSYNMHWVK* – SIL Rituximab signature peptide quantifier
      • ASQSIGTNIHWYQQR* – SIL Cetuximab signature peptide qualifier
      • DYAMTWVR* – SIL Dupilumab signature peptide qualifier
      • GLEWIGAIYPGNGDTSYNQK* – SIL Rituximab signature peptide qualifier
      • Heavy Angiotensin II
      • Heavy calcitonin peptide
      • LEWIGEIDPSESNTNYNQK* – SIL Vedolozumab signature peptide
      • LSITIRPR* – SIL Dupilumab signature peptide quantifier
      • NYLAWYQQKPGK* – SIL Adalimumab signature peptide quantifier
      • QAPGQGLEWMGDINTR* – SIL Emicizumab signature peptide qualifier
      • SGGSIYNEEFQDR* – SIL Emicizumab signature peptide quantifier
      • SINSATHYAESVK* – SIL Infliximab signature peptide quantifier
      • SLEWIGAIDPYYGGTSYNQK* – SIL Dinutuximab signature peptide qualifier
      • SSSTAYMHLK* – SIL Dinutuximab signature peptide quantifier
      • YASESISGIPSR* – SIL Cetuximab signature peptide quantifier
      • YASESMSGIPSR* – SIL Infliximab signature peptide qualifier
    • Antigen peptides, epitopes, pools, libraries
      • A*02:01/Human Survivin (96-104) peptide – LTLGEFLKL
      • A*02:01/Human Survivin/SurA2.M (LMLGEFLKL) peptide
      • Biotin-FluM1 (58-66) peptide
      • Biotin-MAGE-A1 (278-286) peptide
      • Biotin-MAGE-A2 (157-166) peptide
      • Biotin-NY-ESO-1 (157-165) C165V peptide
      • Biotin-Ova (323-339) peptide
      • CD20 (188-196) peptide – SLFLGILSV
      • CMV pp65 (113-121) peptide – VYALPLKML
      • CMV pp65 (120-129) peptide – MLNIPSINV
      • EBV BMLF1 (280-288) peptide – GLCTLVAML
      • Flu-HA-B (306-318) MHC II DRB1*01:01
      • FluM1 (58-66) peptide – GILGFVFTL
      • gp100 (25-33) epitope – KVPRNQDWL
      • gp100 (280-288) A288V HLA-A*0201 antigen peptide – YLEPGPVTV
      • Haemagglutinin (HA) peptide YPYDVPDYA
      • HCV NS5B (2594-2602) peptide – ALYDVVTKL
      • Her-2/neu (85-94) peptide – LIAHNQVRQV
      • HIV-1 p17 Gag (77-85) peptide – SLYNTVATL
      • KD20 peptide
      • MAGE-A p248V9 peptide – YLEYRQVPV
      • MAGE-A p248V9 scrambled (RQYVELPYV)
      • MAGE-A1 (278-286) peptide – KVLEYVIKV
      • MAGE-A1 (278-286) scrambled (ELIVKVYKV)
      • MAGE-A2 (157-166) peptide – YLQLVFGIEV
      • MAGE-A2 (157-166) scrambled (VLVYFQEIGL)
      • MAGE-A3 (112-120) peptide – KVAELVHFL
      • MBP-B MHC II DRB1*15:01 (84-102)
      • Melan-A (26-35) A27L peptide – ELAGIGILTV
      • Melan-A (26-35) peptide – EAAGIGILTV – CAS: 156251-01-3
      • Melan-A (26-35) scrambled (AIEIAGGLTV)
      • MHC binding peptides prediction
      • Myoglobin 137-148 MHC II DRB1*03:01
      • NY-ESO-1 (123-137) DRB1*04:01 peptide – LKEFTVSGNILTIRL
      • NY-ESO-1 (157-165) C165V peptide – SLLMWITQV
      • NY-ESO-1 (157-165) C165V scrambled (MSILWQLVT)
      • NY-ESO-1 (157-165) peptide – SLLMWITQC
      • Ova (323-339) peptide – ISQAVHAAHAEINEAGR
      • OVA 257 264 peptide – SIINFEKL
      • OVA 257 264 peptide SIINFEKL – KLH conjugate
      • OVA 257-264 scrambled (FILKSINE)
      • OVA Peptides Pool
        • OVA Peptides Pool sequences
      • Peptide antigen and epitope catalog
        • PADRE scrambled (AAATLWKAAKFVA)
      • Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV)
      • RS09/Toll Like Receptor TLR4 agonist – APPHALS – CAS 1449566-36-2
      • SYFPEITHI – MHC binding peptide
      • TET 830 modified/T-helper epitope from tetanus toxoid – AQYIKANSKFIGITEL
      • TET 830/Tetanus Toxin (830-844) peptide – QYIKANSKFIGITEL
      • TetTox-B (830-843) MHC II DRB1*07:01
      • TRP-2 Peptide (180-188) – SVYDFFVWL
      • V5 peptide
      • Biotin-PADRE peptide AKFVAAWTLKAAA
      • CEF (HLA Class I Control) Peptide Pool
        • CEF Control Peptide Pool sequences
      • PADRE peptide – AKFVAAWTLKAAA
      • Restricted PADRE peptide- ak(Cha)VAAWTLKAAa-Ahx-C
      • MUC1 (12-20) peptide – LLLLTVLTV
  • Protein synthesis
  • 10 days express peptide synthesis
  • Available options
    • TFA removal service
  • Quality Controls
  • Exclusive benefits
• Proteomic services
  • Additional analyses
  • NMR studies
  • Peptide detection in mixture
  • Peptide & protein purification
  • Mass spectrometry
  • Disulfide bridges determination
  • Peptide quantification
  • Amino acid sequencing